Wire Stories

Category Added in a WPeMatico Campaign

DS_logo_portrait_format_4color_rgb_120206-4

ENHERTU® Demonstrated Clinically Meaningful Progression-Free Survival and Overall Survival Across Multiple HER2 Expressing Advanced Solid Tumors in DESTINY-PanTumor02 Phase 2 Trial

Data support ongoing discussions with global health authorities TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--Topline results from the primary analysis of...

TAK_Logo

The New England Journal of Medicine Publishes Data from Phase 2 Study of First Oral Orexin Receptor 2 Agonist TAK-994 in Patients with Narcolepsy Type 1

Trial Was Stopped Due to Hepatotoxicity and Consequently TAK-994 Program Terminated for Further Development In Patients with Narcolepsy Type 1,...